Icon nabs molecular diagnostic lab to support precision medicine programs

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)

Related tags: Icon, Diagnostics, Precision medicine

Icon acquired the molecular diagnostic laboratory MolecularMD to further support precision medicine programs across all development phases.

Dr. Steve Cutler, Icon CEO said on the company’s recent earrings call that acquisition enhances its laboratory offering in molecular diagnostic tests, “a key area in oncology research.”

The acquisition – terms of which were not disclosed – also expands Icon’s testing platforms with next-generation sequencing and immunohistochemistry. MolecularMD also provides companion diagnostics development services.

“[The acquisition is] not just the enhancement of our lab capabilities. I believe it's an enhancement of our clinical operations and our clinical program management capabilities as well,”​ Cutler added on the call.

An evaluation of the business will be conducted over the next couple of quarters, he noted.

“There are certainly some parts of the business that we look at and we think could be very, very nicely applied and synergized across our businesses. And I talked about that CAR-T and cell-based project expertise in the first-mover advantage we believe we have in that space and how that could be applied,”​ said Cutler.

Icon currently operates a network of fully accredited laboratory facilities, including central laboratories in Dublin, Ireland, Farmingdale NY, Singapore and Tianjin, China, as well as a bioanalytical laboratory in Whitesboro, NY.

The company also earlier this year launched a new drug safety reporting platform​.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Related suppliers

Follow us

Products

View more

Webinars